Subscribe or Manage Preferences

Health Economics

Cost-effectiveness analysis should incorporate net health improvement and a dollar threshold for quality-adjusted life-years, according to some experts.
A team of investigators recommends that clinicians prepare to discuss long-term affordability and relative efficacy of biologic DMARDS with their patients with RA, as out-of-pocket costs are expected to reach a “catastrophic” phase of coverage.
An analysis of a theoretical cohort of patients using a mathematical model suggests that it is cost-effective for morbidly obese individuals to have bariatric surgery prior to total hip arthroplasty (THA), compared with having hip-replacement surgery alone.
How can the high cost of healthcare be spread among all stakeholders to produce the biggest patient-care bang for the buck?
The most comprehensive database in the United States on total hip and knee joint replacements (TJRs) and outcomes establishes benchmarks for these surgeries and offers new insights into appropriateness criteria and timing of surgeries that will enable value-based care.
The AIM FARTHER program developed at Geisinger Health System in Pennsylvania is a unique initiative designed to improve the quality of care for patients with rheumatoid arthritis (RA) and reduce costs.
Blue Cross Blue Shield (BCBS) is implementing value-based care and payment models across the country to reward quality and improve outcomes, and these are amounting to billions of dollars in cost-savings and reduced hospitalizations.
Tampa, FL—Post-hoc analyses of the phase 3 trials, ORAL Standard and ORAL Step, revealed that tofacitinib––a novel oral Janus kinase inhibitor––and adalimumab led to lower monthly medical expenditures (MMEs) compared with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) who did not respond to either methotrexate or tumor necrosis factor (TNF) inhibitors, according to investigators Regina Rendas-Baum, MS, scientist at QualityMetric, and colleagues.
Montreal, QC—What is the impact of value-based pricing across indications on medical practices and their patients? That question is on the minds of healthcare professionals in all areas of medicine, including rheumatology.
Paris, France—Nonadherence to medications is widespread in rheumatologic diseases, but the literature is sparse as to how this impacts healthcare outcomes and costs, according to speakers at the 2014 European League Against Rheumatism Congress.
Page 1 of 4
Results 1 - 10 of 40
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology